Evercore ISI lowered the firm’s price target on Becton Dickinson (BDX) to $275 from $290 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Citi analysis yields ‘substantial upside’ in Becton Dickinson shares
- Becton Dickinson discloses resolution with SEC over Alaris System invesigation
- Becton, Dickinson Reports Strong Fiscal 2024 Results
- Morning Movers: Under Armour and Lyft soar following earnings
- Becton Dickinson sees FY25 adjusted EPS $14.25-$14.60, consensus $14.34